This morning the Federal Circuit issued one nonprecedential opinion in a patent case. Here is the introduction to the opinion.
Pfizer, Inc. v. Chugai Pharmaceutical Co. (Nonprecedential)
Chugai Pharmaceutical Co., Ltd., owns U.S. Patent Nos. 7,332,289 (“the ’289 patent”) and 7,927,815 (“the ’815 patent”). In two inter partes review proceedings, Pfizer Inc. petitioned the Patent Trial and Appeal Board to invalidate most of the claims of the ’289 and ’815 patents. In each IPR, the Board held that Pfizer did not prove that any of the challenged claims were unpatentable, and Pfizer appealed. Because Pfizer has failed to establish that it has Article III standing for purposes of the proceedings before this court, we dismiss both appeals.